Resolution n°3-2022-e

Further investments to enhance access to COVID-19 therapeutics and ancillary products in low- and middle-income countries

Recalling a Request for Proposals launched by the Secretariat seeking proposals aimed at “Enhancing access to COVID-19 test, isolate, care and treatment innovations within healthcare systems in LMICs”; and noting that selected investment in projects were approved in accordance with the Board-approved COVID-19 investment processes set out in Resolution R5-2020-e, as amended by Resolutions R7-2020-e and R3-2021-e, together with Resolution EB35/2020/R4;

Referring to five existing Unitaid projects approved through this process, as follows:

- “Improving Public Health Outcomes through Enhancing Accelerated Access to Care and Treatment Innovation for COVID-19” (IMPACT4C19) – Lead Implementer: The Aurum Institute;
- “Catalyzing COVID-19 ACTION” – Lead Implementer: Elizabeth Glaser Pediatric AIDS Foundation;
- “Enhancing access to COVID-19 test, isolate, care and treat interventions within healthcare systems in LMICs” - Lead Implementer: Clinton Health Access Initiative;
- “Enhanced and Equitable Coverage of COVID-19 Testing and Treatment in Bolivia and Paraguay” - Lead Implementer: IS Global; and

Recognizing that, as the co-lead of the Access to the COVID-19 Tools Accelerator (ACT-A) Therapeutics Pillar, Unitaid is uniquely positioned to leverage its existing network of Unitaid-funded projects, in order to rapidly deliver targeted, catalytic investments that support essential evidence generation for new tools, together with country preparedness and early introduction of key COVID-19 commodities, in line with ACT-A’s established priorities; and

Taking into account the recommendations of the Secretariat and the PRC, the Executive Board authorises the Executive Director to commit up to a further US$ 22,000,000 to the five Unitaid projects listed above, to fund the procurement and allocation to the five projects of newly recommended and pipeline COVID-19 therapeutic products, together with ancillary products that are essential for the delivery of the therapeutic products including additional laboratory tests.
This Board authorisation is provided on the following basis:

1. Products will be selected for procurement by the Secretariat following consultation with ACT-A partners through the Therapeutics Pillar, including WHO;
2. The selected products will be procured principally through i+Solutions, on terms equivalent to those available to the Global Fund under its Long-Term Agreement with i+Solutions. However, exceptionally, the Secretariat may also procure through WHO’s Health Emergencies Programme where it considers that doing so will optimise specific procurement arrangements;
3. Procurement orders will be placed by the Secretariat within 12 months of this Board decision;
4. The allocation of procured products across the five projects listed above will be flexible and determined by the Secretariat following ACT-A partner consultations.

The Board authorises the Executive Director to sign amendments to the funding agreements for each of the projects increasing the project budget ceilings by the amount of the funding disbursed by Unitaid for the procurement of products for the project. It is nevertheless noted that no funding will be disbursed to the five projects under this authorisation.

Recognising that the procurement is targeted to cover up to twelve months of product supplies across the five projects, the Board also authorises the Executive Director to extend the duration of the five projects up to 31 March 2023, to allow the implementation through the projects of the arrangements authorised through this decision.

Marisol Touraine  
Chair of the Unitaid Executive Board

Date: 11.02.2022